Last updated on December 2019

A Phase 1/2 Study of In Situ Vaccination With Tremelimumab and IV Durvalumab Plus PolyICLC in Subjects With Advanced Measurable Biopsy-accessible Cancers


Brief description of study

This is an open-label, multicenter Phase 1/2 study of the CTLA-4 antibody, tremelimumab, and the PD-L1 antibody, durvalumab (MEDI4736), in combination with the tumor microenvironment (TME) modulator polyICLC, a TLR3 agonist, in subjects with advanced, measurable, biopsy-accessible cancers.

Clinical Study Identifier: NCT02643303

Find a site near you

Start Over

Research Facility

Cleveland, OH United States
  Connect »

Research Facility

Charlottesville, VA United States
  Connect »

Research Facility

Atlanta, GA United States
  Connect »

Research Facility

Lebanon, NH United States
  Connect »

Research Facility

Buffalo, NY United States
  Connect »

Research Facility

New York, NY United States
  Connect »

Research Facility

Toledo, OH United States
  Connect »